tradmap

CRIS CURIS INC

$1.36 -2.16%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

CURIS INC (CRIS) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $3 million. Shares last traded at $1.36, 96.1% below their 52-week high. Over the past year the stock is down 95.5%. Net profit margin is -224.0%, below the peer median of 5.3%. Revenue declined 13.4% year over year.

Market Cap
$3M
Shares Out
2.1M
EPS (TTM)
$-60.85
P/E Ratio
P/S Ratio
0.30
P/B Ratio
0.61
Dividend / Share
Dividend Yield
52-Week High
$34.56
52-Week Low
$1.36
Volume
2,001
Avg Vol (3m)
4,577.384

Performance

1W
-10.53%
1M
-69.61%
3M
-84.90%
6M
-92.74%
YTD
-92.33%
1Y
-95.50%

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. CRIS split history →

Technicals

RSI (14)
20.88
SMA (50)
$3.87
SMA (200)
$12.17
Price vs SMA50
-64.86%
Price vs SMA200
-88.83%
ATR (14)
$0.29

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$9M
Net Income
$-21M
Gross Margin
Operating Margin
-92.8%
Net Margin
-224.0%
Return on Equity
-450.5%
Return on Assets
-111.5%
Current Ratio
0.49
Debt / Equity
0.00
Revenue Growth (YoY)
-13.4%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-21.08 2026-08-14
Q1 2026 $-1.25 2026-05-13
FY 2025 $-0.58 2026-03-24
Q3 2025 $-2.19 2025-11-06
Q2 2026 $-36.33 2026-08-14
Q1 2026 $-1.25 2026-05-13

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

CRIS vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
0.30 / 19.49 med
-98% discount
Net margin vs peers
-224.0% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.